27 results
8-K
EX-3.4
RETA
Reata Pharmaceuticals Inc
26 Sep 23
Termination of a Material Definitive Agreement
5:25pm
or engagement or to pledge its credit or to render it liable pecuniarily for any purpose or to any amount.
SECTION 5.02. Deposits. All funds
8-K
EX-3.2
RETA
Reata Pharmaceuticals Inc
26 Sep 23
Termination of a Material Definitive Agreement
5:25pm
have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable pecuniarily for any
DEFM14A
RETA
Reata Pharmaceuticals Inc
22 Aug 23
Proxy related to merger
8:00am
is not a recommendation as to how any holder of the shares of Common Stock should vote with respect to the Merger or any other matter. Pursuant to an engagement letter … engagement with Goldman Sachs and authorized members of Reata’s senior management to execute an engagement letter with Goldman Sachs.
Following the Board
PREM14A
RETA
Reata Pharmaceuticals Inc
11 Aug 23
Preliminary proxy related to merger
4:38pm
should vote with respect to the Merger or any other matter. Pursuant to an engagement letter between the Company and Goldman Sachs, Reata has agreed … of a customary termination fee. Lastly, after excusing Goldman Sachs from the meeting, the Board also reconfirmed the terms of Reata’s engagement
8-K
EX-99.2
3kqz1iu1
10 May 23
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
6:45am
8-K
EX-99.2
57fg52
10 May 22
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
6:48am
8-K
EX-1.1
rtnmrw5k1d 43
3 Dec 20
Entry into a Material Definitive Agreement
4:45pm